Form 6-K XTL BIOPHARMACEUTICALS For: Dec 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Tanker struck by projectile in Strait of Hormuz
XTL Biopharm SP (XTLB) Swings to Q3 Loss
December 1, 2014 6:40 AM ESTXTL Biopharm SP (Nasdaq: XTLB) reported Q3 EPS of $-0.00, versus $0.00 reported last year. Revenue was $287 thousand, versus $473 thousand posted in Q313.
For earnings history and earnings-related data on XTL Biopharm SP (XTLB) click here.
... More